Navigation Links
GeoVax Labs Reports 2012 First Quarter Financial Results
Date:5/15/2012

icate superior protection when compared to similar viral challenge studies for competitive vaccine designs currently in human clinical trials. We are therefore very excited about the potential for our vaccine."

Dr. McNally continued, "On the financial side, we continue to benefit from NIH/HVTN support of our human clinical trials and we are seeking additional government support to fund our internal research and development activities to expand the use of our technology against strains (clades) of the HIV virus affecting other areas of the globe. From December 2011 to March 2012, we raised a total of $2.7 million in equity capital to bolster our cash reserves."

Comment on Gilead Science's Truvada® Prevention SubmissionDr. McNally also commented on the recent news related to an advisory panel's recommendation that the FDA approve Gilead Science's submission of their anti-viral medication, Truvada, for prevention of HIV. "While any positive step towards the control of this deadly disease is greatly welcomed, we must continue the search for safe, cost-effective measures to prevent HIV transmission. The high cost of oral medications, patient compliance, and risk of medical side effects clearly suggest the best solution still lies with a preventive vaccine. GeoVax's preventive vaccine is considered a leading candidate for the version of the virus prevalent in North and South America, and Europe."

Financial ReviewGeoVax reported a net loss for the three months ended March 31, 2012 of $730,513, or $0.04 per share, based on 16.7 million weighted average shares outstanding. For the three months ended March 31, 2011, the Company reported a loss of $606,282, or $0.04 per share, based on 15.7 million weighted average shares outstanding.

The Company reported revenues of $854,063 for the three months ended March 31, 2012, related to its Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant from the National Institutes
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. GeoVax Labs CEO Update Letter to Shareholders
2. GeoVax Labs First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine
3. GeoVax Phase 2a Clinical Trial Completes Enrollment
4. GeoVax $3.6 Million Award Increased to $4.4 Million by U.S. Government
5. GeoVax Labs, Inc. Announces Second Quarter Financial Results
6. GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress
7. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
8. GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
9. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
10. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
11. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , Oct. 24, 2014  Heska Corporation (Nasdaq: ... Invites You to Join Its Third Quarter 2014 Earnings ... 9:00 a.m. (MDT) / 11:00 a.m. (EDT)Where: , ... link on the front page of this website)How:Live over ... at the address above.  Alternatively, you may use the ...
(Date:10/25/2014)... --  Metanome, Inc. , a Houston ... was the genomic sequencing provider for Seres Health,s ( ... of SER 109, an Ecobiotic® therapeutic for the treatment ... (CDI). Metanome has provided genomic sequencing services ... Such genomic characterization has enabled the study of the ...
(Date:10/25/2014)... , Oct. 24, 2014 Best ... Medical Affairs leaders with a forum for sharing ... consortium has developed a mechanism for creating and ... leaders discuss key findings from the Medical Affairs ... completed the analysis for the first roundtable of ...
Breaking Medicine Technology:Webcast Alert: Heska Announces Third Quarter 2014 Earnings Conference Call Webcast 2Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2Strong Participation in Best Practices' Medical Affairs Consortium Survey 2
... ,   Amcor ... €6.7 million in its Singen converting plant ... production of pharmaceutical packaging,and upgrades the classic ... industry.      (Logo:  http://www.newscom.com/cgi-bin/prnh/20110630/465056  ) ...
... June 29, 2011 CardioGenics Holdings Inc. (CGNH.OB) ... Trademark Office (USPTO) has notified the company that ... # 7,964,415). This patent covers ... is a key component of the core technology ...
Cached Medicine Technology:Amcor Invests €6.7 Million in the Extension of its Singen Converting Plant in Germany 2USPTO Issues Patent for CardioGenics' Signal Amplification Technology 2
(Date:10/25/2014)... (PRWEB) October 25, 2014 Background: , ... Recovery (CCAR). He is a pioneer in the field of ... in Connecticut's state treatment system and when he retired, he ... him while in public service. , 1. ... critical decisions concerning them? , 2. Can the recovery ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 ... Molecular Diagnostics Industry, 2009-2019 is a professional ... Chinese Molecular Diagnostics industry. The report firstly ... including its classification, application and manufacturing technology. ... top manufacturers of Molecular Diagnostics listing their ...
(Date:10/25/2014)... New York (PRWEB) October 25, 2014 ... mesh lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed against ... underway in U.S. District Court, Southern District of ... Summary Judgment on Punitive Damages in a group ... In a ruling issued on October 21st, U.S. ...
(Date:10/25/2014)... (HealthDay News) -- Interrupting blood supply to an arm or ... associated with the surgery, according to a new study. ... supply to the heart to be able to operate on ... reduce its ability to produce energy because it doesn,t get ... large muscle, such as an arm or a leg, the ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Researchers who ... their findings are cause for concern. The ... are raised for human consumption contribute to the ... according to background information from the study. ... sicken about 2 million people and kill about ...
Breaking Medicine News(10 mins):Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2
... increasingly important method for detecting malaria. Health specialists recommend ... other strategies for controlling the disease // , including ... indoor spraying against malaria-carrying mosquitoes and testing and treatment ... tests are ideal for rural areas are accurate, easy ...
... Researchers find that aspirin saves the life of cancer ... believe that majority of these patients will die// if ... turns common medical assumptions upside down and will likely ... thin blood and cancer patients experience low platelet counts ...
... The experts in this weeks' BMJ, have reported that ... work together to restore faith in drug development//. ... drug Vioxx, produced by Merck and Co. Inc., has ... be open to abuse. ,Vioxx (rofecoxib) ...
... explains - how beneficial traits accumulate in natural populations, but ... two theories have addressed this problem. The theory of hitchhiking ... can become common in natural populations when they "hitch a ... selection. ,Conversely, the theory of kin selection ...
... Drugs that Facilitate and/or Prevent Diabetes//. ... develop new-onset diabetes than those who don’t have hypertension, ... recent weight gain, or stronger family history of diabetes ... have known since 1958 that some drugs used to ...
... children with persistent fluid in the middle ear// need not ... , It is generally believed that ear fluid has to ... study suggests that inserting ear tubes to remove ear fluid ... years of age. This important study was conducted at Children’s ...
Cached Medicine News:Health News:New Tests Promise Rapid and Accurate Detection of Malaria 2Health News:New Tests Promise Rapid and Accurate Detection of Malaria 3Health News:Aspirin Saves Life Even in Cancer Patients 2Health News:Aspirin Saves Life Even in Cancer Patients 3Health News:New Approach Needed To Restore Faith in Pharmaceutical Industry 2Health News:Study Explains How Costly Traits Evolve 2Health News:Differences Between BP Medicines and Newly-Diagnosed Diabetes Identified 2Health News:Differences Between BP Medicines and Newly-Diagnosed Diabetes Identified 3Health News:Ear Fluid Does Not Impair Development 2Health News:Ear Fluid Does Not Impair Development 3Health News:Ear Fluid Does Not Impair Development 4
Sandhill Scientific offers a comprehensive selection of solid state and water perfused catheters for both adult & pediatric applications.Contact Sandhill Scientific for full details...
... of single-use products to promote safety for ... single-use catheter reduces cross-contamination and helps protect ... and, because cleaning is eliminated, you have ... have water perfused manometric catheters for esophageal, ...
... Air-Charged Catheters make motility ... Disposable Latitude catheters set up ... cross-contamination. And with every sensor ... by eliminating anatomical irregularities. For ...
Polygraf ID Adapter Cable for LATITUDE® Air-Charged Catheter...
Medicine Products: